Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
7.57M | 5.12M | 9.03M | 12.00M | 0.00 | Gross Profit |
5.71M | 4.38M | 8.31M | 11.53M | -229.00K | EBIT |
-65.92M | -65.76M | -21.30M | -30.91M | -40.18M | EBITDA |
-65.90M | -62.20M | -21.60M | -30.31M | -39.43M | Net Income Common Stockholders |
-76.58M | -67.00M | -27.68M | -38.90M | -45.50M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
46.33M | 69.55M | 34.27M | 70.35M | 65.47M | Total Assets |
54.13M | 81.60M | 44.72M | 80.13M | 74.15M | Total Debt |
45.94M | 45.51M | 1.53M | 43.41M | 35.31M | Net Debt |
-390.00K | -24.04M | -32.75M | 27.66M | 24.63M | Total Liabilities |
63.99M | 61.83M | 4.69M | 47.52M | 41.17M | Stockholders Equity |
-9.86M | 19.76M | 40.03M | 32.60M | 32.99M |
Cash Flow | Free Cash Flow | |||
-60.95M | -38.94M | -18.95M | -28.46M | -31.68M | Operating Cash Flow |
-60.93M | -38.58M | -18.65M | -27.58M | -30.21M | Investing Cash Flow |
-19.00K | -362.00K | 54.04M | -998.00K | -3.58M | Financing Cash Flow |
37.73M | 74.21M | -16.87M | 33.65M | 35.23M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | $839.35M | ― | -913.07% | ― | 31.76% | 24.85% | |
49 Neutral | $6.87B | 0.03 | -54.93% | 2.50% | 24.65% | -2.90% | |
44 Neutral | $28.14M | ― | -56.54% | ― | 18.16% | 86.65% | |
42 Neutral | $5.59M | ― | -57.34% | ― | ― | ― | |
39 Underperform | $110.93M | ― | -129.58% | ― | -27.69% | -27.91% | |
38 Underperform | $49.31M | ― | -2059.89% | ― | 187.45% | -69.90% | |
36 Underperform | $1.96M | ― | 52.08% | ― | -32.57% | -15.03% |
Verrica Pharmaceuticals Inc. has appointed David Zawitz as its new Chief Operating Officer, effective December 9, 2024. Zawitz, who has an extensive legal and financial background, including roles at PBM Capital Group and CarMax, will receive an annual salary of $250,000 and is eligible for stock options and bonuses. This strategic move is part of the company’s broader plan to expand its stock option pool, aiming to attract top talent and strengthen its position in the financial market.
Verrica Pharmaceuticals is undergoing significant leadership changes and financial restructuring as it navigates challenges and opportunities in the dermatology sector. Ted White has stepped down as CEO, with Dr. Jayson Rieger taking his place and John Kirby appointed as Interim CFO. The company reported negative net product revenue in Q3 2024 due to product returns and is focusing on reducing operating expenses and enhancing market access for its molluscum treatment, YCANTH. Verrica has engaged Jefferies as a financial advisor to explore ways to strengthen its balance sheet.